ADPKD
24
6
7
11
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
12.5%
3 terminated out of 24 trials
78.6%
-7.9% vs benchmark
29%
7 trials in Phase 3/4
45%
5 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (24)
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
Somatosensory Phenotyping of ADPKD
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
Statin Therapy in Patients With Early Stage ADPKD
Kidney Sodium Functional Imaging
Analysis of Patients With Autosomal Dominant Polycystic Kidney
Genetic Testing in Autosomal Dominant Polycystic Kidney Disease
Genetics in the Progression of Nephropathies
Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping
Short Term Induction of Ketosis in PKD
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
ADPKD Alterations in Hepatic Transporter Function
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)